Dendritic Cell Vaccine With Imiquimod for Patients With Malignant Glioma
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Brain Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | October 2009 |
| End Date: | October 2016 |
A Phase I Trial of Surgical Resection Followed by Vaccination With Dendritic Cells Pulsed With Tumor Lysate With Imiquimod for Patients With Malignant Glioma
Malignant gliomas are very aggressive and among the most common of brain tumors. A diagnosis
carries with it a median survival of approximately 24 months. The current standard treatment
of surgical resection followed by radiation therapy and chemotherapy has not substantially
prolonged survival and even the few treatment options shown to exhibit small increases in
survival primarily benefit certain (i.e., young) patient subpopulations.
Cancer vaccines represent one novel therapy for malignant gliomas. The goal is for the body
to recognize the tumor cells are foreign and produce its own response to fight off recurring
tumor cells. A promising means of causing an immune response so the body can create this
immunity is through the use of dendritic cell (DC) vaccines.
carries with it a median survival of approximately 24 months. The current standard treatment
of surgical resection followed by radiation therapy and chemotherapy has not substantially
prolonged survival and even the few treatment options shown to exhibit small increases in
survival primarily benefit certain (i.e., young) patient subpopulations.
Cancer vaccines represent one novel therapy for malignant gliomas. The goal is for the body
to recognize the tumor cells are foreign and produce its own response to fight off recurring
tumor cells. A promising means of causing an immune response so the body can create this
immunity is through the use of dendritic cell (DC) vaccines.
Dendritic cells are a small group of cells contained in everyone's white blood cell
population. These cells are responsible for letting the immune system know that something
foreign is in the body. Dendritic cells help the body ward off disease by alerting the
immune system.
Imiquimod in an FDA-approved cream that is an immune response modifier, which will be used
off-label in this study. Imiquimod cream (5%, 250 mg) will be self-applied topically by
patients to a 4 x 5-cm outlined area of healthy skin overnight on days 1-5 of each cycle.
Application and removal times will be recorded in treatment diaries. Dendritic cells will be
injected intradermally into the imiquimod-treated site on day 3. Cycles will be repeated
every 2 weeks for a total of three injections. This study will examine the effectiveness of
using Imiquimod with DC vaccines, as previous studies within the oncology department have
studied the effectiveness of DC vaccines.
Imiquimod (Aldara, 3M) is one of the better characterized imidazoquinolines and is the only
one currently approved for clinical use as a topical ointment. It has been demonstrated to
possess antiviral and antitumor properties, and it is approved for the treatment of genital
warts. Vaccination studies in animal models have indicated that imidazoquinolines can boost
the magnitude and quality of T cell responses. It is considered a Toll-like receptor agonist
which controls the activation of dendritic cells.
In humans, it was shown that topical imiquimod treatment may enhance the immunogenicity of a
melanoma vaccine. Additionally, injection of immature DCs into imiquimod-pretreated skin
lead to DC activation in situ and enhanced migratory capacity to draining lymph nodes in
cancer patients. In this study, the investigators test the safety and feasibility of
imiquimod in a vaccine against brain cancer to induce a more potent immune response that
what has previously been observed.
In prior Phase I and Phase II studies, patients who received chemotherapy following DC
demonstrated longer progression free and overall survival than the patients who received DC
or chemotherapy alone. The use of DC vaccines is considered investigational and has not yet
been approved by the FDA, but the investigators have obtained an IND for use of the
vaccines.
The purpose of this study is to determine whether after standard therapy of tumor resection
surgery followed by DC vaccines with Imiquimod will not only generate (start) an immune
response, but will provide longer progression-free survival. Subjects will have clinically
indicated resection surgery and will consent to our screening study for vaccine trials (IRB
#9225), under which subjects will have their tumor tissue analyzed in order to verify
eligibility into this study.
Study procedures include the following: laboratory blood draws, urinalysis at screening,
immunological testing, administration of the quality of life questionnaire, neurological
exams, MRI testing, leukapheresis for dendritic cells, review of adverse events/concomitant
medications.
Patients who were screened and not enrolled in this clinical trial due to screen failure
will be notified of the reason for screen failure. Pre HIV counseling and appropriate
referral resources will be provided. If the screen failure is due to the positive HIV test,
appropriate post HIV counseling will be provided and appropriate referrals will be made. The
charts of the patients with screen failures will be destroyed. The patients' charts who will
be enrolled in the study will be kept in the locked cabinet in the research office. Patients
will be assigned a unique identifying code known only to the research team. Data will be
captured by various source documents, or, as necessary, abstracted from hospital medical
records by an experienced registered nurse. The electronic data for viral testing will be
accessible to research personnel only.
population. These cells are responsible for letting the immune system know that something
foreign is in the body. Dendritic cells help the body ward off disease by alerting the
immune system.
Imiquimod in an FDA-approved cream that is an immune response modifier, which will be used
off-label in this study. Imiquimod cream (5%, 250 mg) will be self-applied topically by
patients to a 4 x 5-cm outlined area of healthy skin overnight on days 1-5 of each cycle.
Application and removal times will be recorded in treatment diaries. Dendritic cells will be
injected intradermally into the imiquimod-treated site on day 3. Cycles will be repeated
every 2 weeks for a total of three injections. This study will examine the effectiveness of
using Imiquimod with DC vaccines, as previous studies within the oncology department have
studied the effectiveness of DC vaccines.
Imiquimod (Aldara, 3M) is one of the better characterized imidazoquinolines and is the only
one currently approved for clinical use as a topical ointment. It has been demonstrated to
possess antiviral and antitumor properties, and it is approved for the treatment of genital
warts. Vaccination studies in animal models have indicated that imidazoquinolines can boost
the magnitude and quality of T cell responses. It is considered a Toll-like receptor agonist
which controls the activation of dendritic cells.
In humans, it was shown that topical imiquimod treatment may enhance the immunogenicity of a
melanoma vaccine. Additionally, injection of immature DCs into imiquimod-pretreated skin
lead to DC activation in situ and enhanced migratory capacity to draining lymph nodes in
cancer patients. In this study, the investigators test the safety and feasibility of
imiquimod in a vaccine against brain cancer to induce a more potent immune response that
what has previously been observed.
In prior Phase I and Phase II studies, patients who received chemotherapy following DC
demonstrated longer progression free and overall survival than the patients who received DC
or chemotherapy alone. The use of DC vaccines is considered investigational and has not yet
been approved by the FDA, but the investigators have obtained an IND for use of the
vaccines.
The purpose of this study is to determine whether after standard therapy of tumor resection
surgery followed by DC vaccines with Imiquimod will not only generate (start) an immune
response, but will provide longer progression-free survival. Subjects will have clinically
indicated resection surgery and will consent to our screening study for vaccine trials (IRB
#9225), under which subjects will have their tumor tissue analyzed in order to verify
eligibility into this study.
Study procedures include the following: laboratory blood draws, urinalysis at screening,
immunological testing, administration of the quality of life questionnaire, neurological
exams, MRI testing, leukapheresis for dendritic cells, review of adverse events/concomitant
medications.
Patients who were screened and not enrolled in this clinical trial due to screen failure
will be notified of the reason for screen failure. Pre HIV counseling and appropriate
referral resources will be provided. If the screen failure is due to the positive HIV test,
appropriate post HIV counseling will be provided and appropriate referrals will be made. The
charts of the patients with screen failures will be destroyed. The patients' charts who will
be enrolled in the study will be kept in the locked cabinet in the research office. Patients
will be assigned a unique identifying code known only to the research team. Data will be
captured by various source documents, or, as necessary, abstracted from hospital medical
records by an experienced registered nurse. The electronic data for viral testing will be
accessible to research personnel only.
Inclusion Criteria:
- Patients must have a histopathological diagnosis of malignant glioma.
- Patients 18 years of age or older.
- Patients must have undergone maximal surgical resection of malignant glioma
- Both male and female of childbearing age entering the protocol must use a medically
accepted form of birth control during the study, will be required to have a negative
pregnancy test for female.
- Patients must have a Karnofsky performance score of at least 60%.
- Patients must be off steroids for at least two weeks prior to vaccination.
- Baseline hematologic and complete metabolic panel within one week of initiating
therapy must fall within normal ranges
- Patient must be capable of signing IRB approved Research Consent and Release of
Medical Records form.
Exclusion Criteria:
- Severe pulmonary, cardiac or other systemic disease associated with an unacceptable
anesthetic or operative risk.
- The presence of an acute infection requiring active treatment will be criteria for
delay or exclusion.
- Contraindication to MRI procedure unless otherwise determined by PI.
- Patients with a known history of an autoimmune disorder.
- Pregnancy.
- Patients positive for hepatitis B, hepatitis C, HIV I/II, syphilis, HTLV I/II, HCV.
- Patients with allergy to Gentamicin.
- Patient inability to participate as determined by PI discretion.
We found this trial at
1
site
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
Click here to add this to my saved trials
